Tedizolid
Mechanism :
Tedizolid binds to the 50S bacterial ribosomal subunit. This prevents the formation of a functional 70S initiation complex that is essential for the bacterial translation process and subsequently inhibits protein synthesis.
Indication :
- Treatment of adult patients with acute bacterial skin and skin structure infections(ABSSSI) caused by gram-positive microorganisms
Contraindications :
No contraindications.
Dosing :
<18 years: Safety and efficacy not established.
200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 18 years of age or older.
Adverse Effect :
Nausea, headache, diarrhea, anemia, vomiting, thrombocytopenia, dizziness.
Interaction :
Buprenorphine, Bupropion, Cyproheptadine, Dextromethorphan: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.
Hepatic Dose :
No dosage adjustments are recommended.